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Knowledge of the beneficial effects of perinatal derivatives (PnD) in wound healing goes
back to the early 1900s when the human fetal amniotic membrane served as a biological
dressing to treat burns and skin ulcerations. Since the twenty-first century, isolated cells
from perinatal tissues and their secretomes have gained increasing scientific interest, as
they can be obtained non-invasively, have anti-inflammatory, anti-cancer, and anti-fibrotic
characteristics, and are immunologically tolerated in vivo. Many studies that apply PnD in
pre-clinical cutaneous wound healing models show large variations in the choice of the
animal species (e.g., large animals, rodents), the choice of diabetic or non-diabetic animals,
the type of injury (full-thickness wounds, burns, radiation-induced wounds, skin flaps), the
source and type of PnD (placenta, umbilical cord, fetal membranes, cells, secretomes,
tissue extracts), the method of administration (topical application, intradermal/
subcutaneous injection, intravenous or intraperitoneal injection, subcutaneous
implantation), and the type of delivery systems (e.g., hydrogels, synthetic or natural
biomaterials as carriers for transplanted cells, extracts or secretomes). This review
provides a comprehensive and integrative overview of the application of PnD in wound
healing to assess its efficacy in preclinical animal models. We highlight the advantages and
limitations of the most commonly used animal models and evaluate the impact of the type
of PnD, the route of administration, and the dose of cells/secretome application in
correlation with the wound healing outcome. This review is a collaborative effort from
the COST SPRINT Action (CA17116), which broadly aims at approaching consensus for
different aspects of PnD research, such as providing inputs for future standards for the
preclinical application of PnD in wound healing.
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INTRODUCTION
Human skin is the largest organ of the body that provides
complex functions. It protects the body against mechanical,
chemical, and physical impact, as well as dehydration. In
addition, it modulates the body temperature and serves as a
sensory organ. The compact part of the skin, the cutis, consists of
the epidermis, a keratinized stratified squamous epithelium, and
the underlying dermis, which is built from connective tissue.
Below the cutis is the loosely-layered subcutis, which is enriched
by adipose tissue.
Severe skin injury is the result of wounds caused by incision,
excision, abrasion, burn, radiation or pressure. The degree of
wounding describes the depth of damage to the respective skin
layers. In first-degree wounds, only the epidermis is affected, in
second-degree wounds, the epidermis and dermis are affected,
and in third-degree wounds, all three skin layers including the
subcutis are affected.
Skin damage is repaired by wound healing, a multistep, finely
orchestrated process that includes hemostasis, inflammation,
tissue growth (proliferation), and tissue remodeling
(maturation) (Xue et al., 2018). This process is highly efficient
in healthy individuals. However, the type, extent, and depth of
injury, as well as any deviations in the fragile wound repair
response, affect the healing outcome. Parameters such as aging,
comorbidities (e.g., diabetes, obesity, arterial or venous
insufficiencies, autoimmune diseases), and severe burn injuries
constitute some of the causes that delay wound healing, often due
to insufficient blood supply based on impaired wound
revascularization (Demidova-Rice et al., 2012). Non-healing
wounds that persist for more than 3 months are called chronic
wounds. These types of wounds have failed to proceed through an
orderly and timely reparative process to produce anatomic and
functional integrity of the injured site (Lazarus et al., 1994) and
are often detained in a self-perpetuating inflammatory stage that
hinders progression to proliferation (Stojadinovic et al., 2008).
Approximately 40 million patients worldwide suffer from chronic
wounds, which are still a challenge to treat and constitute a
significant financial burden on the health care system (Sen et al.,
2009). Thus, new therapeutic approaches for wound healing are
highly warranted.
A promising strategy for wound treatment is the application of
human perinatal derivatives (PnD). PnD are birth-associated
tissues such as the placenta and its annexes (human amniotic
membrane (hAM), chorionic membrane, decidua, umbilical
cord) and the amniotic fluid. PnD are an abundant source of
extracellular matrix proteins, growth factors, and cells that have
already been used in a wide variety of applications in tissue
engineering and regenerative medicine (Deus et al., 2020). The
application of the hAM has a long tradition in the treatment of
wounds. Early studies from 1909 to 1913 reported successful use
of the hAM in skin transplantation (Davis, 1909) and for treating
burns and skin ulcerations as a biological dressing. Its use
significantly reduced pain and increased the epithelialization
rate of the traumatized skin without signs of infection (Sabella,
1913; Stern, 1913). Several clinical trials in the subsequent
decades confirmed the successful use of the hAM for skin
injuries (Silini et al., 2015). The twenty-first century brought
the breakthrough for cell isolations from different placental
regions and the progressive investigation of their therapeutic
potential. Minimal criteria for the definition of PnD derived cells
were described in 2008 (Parolini et al., 2008), and ongoing
extensive characterization of PnD was performed (Caruso
et al., 2012; Silini et al., 2020).
PnD derived cells have anti-inflammatory,
immunomodulatory, anti-cancer, anti-fibrotic, anti-apoptotic,
and anti-oxidant effects. They are immunologically tolerated in
vivo and have been transplanted without signs of immunological
rejection, meaning that the application does not require
immunosuppressive treatment (Ueta et al., 2002; Bailo et al.,
2004; Jirsova and Jones, 2017).
With the expanding knowledge that cells act by paracrine
mechanisms, the released secretomes (cell-derived conditioned
media, cell-derived extracellular vesicles) are gaining increasing
interest. Placental cells secrete factors that are crucial for wound
healing such as EGF, IL-8, and IGF-1, which modulate migration
and proliferation of keratinocytes, fibroblasts, and endothelial
cells (Kim et al., 2012). hAM mesenchymal stromal cells
(hAMSC) and their secretomes exhibit beneficial, survival-
enhancing effects on endothelial cells in vitro and were shown
to stabilize endothelial networks in the Matrigel assay (König
et al., 2012; König et al., 2015). Further, co-transplantation of
hAMSC and placental endothelial cells enabled the formation of
human capillaries connecting to the murine blood circulation in a
mouse model in vivo (Kinzer et al., 2014).
As the formation of new blood vessels is critical for normal
wound healing, innovations to improve wound revascularization
could also lead to significant advances in wound healing therapy
and patient care (Demidova-Rice et al., 2012). Improved
techniques for tissue preservation, and recent advances in
isolation and culture procedures for PnD derived cells paved
the way for established clinical uses and investigative pre-clinical
and clinical trials such as the application of placenta derived
mesenchymal stromal-like cells (PDA-002) for the treatment of
patients with diabetic foot ulcer wounds and peripheral arterial
disease (Silini et al., 2015)1.
This review provides a thorough overview of the application of
PnD in wound healing to assess its efficacy in preclinical animal
models based on different wound types. We highlight the
advantages and limitations of the most commonly used animal
models and evaluate the impact of the type of PnD, the delivery
method and the dose of cells/secretome application in correlation
with the wound healing outcome.
METHODS AND SEARCH STRATEGY TO
COLLECT THE DATA
We performed a systematic literature search of the PubMed®
database covering a period from 2004 to 2020 and used the
Boolean search string (Supplements) in accordance with the
1https://clinicaltrials.gov/
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consensus of the scientific network of the COST SPRINT Action
(CA17116) to identify articles exploring therapeutic options of
PnD in in vivo experimental models of wound healing. Titles and
abstracts were screened to select publications including in vivo
models evaluating the efficacy of PnD. The search was limited to
original research publications available as full text in English. The
publications were cross-checked for meeting the inclusion criteria
by an independent study. The selection workflow was compliant
with the PRISMA guidelines (Page et al., 2021a; Page et al.,
2021b).
We obtained 141 manuscripts investigating the application of
PnD to animal wound- or angiogenic models. We further focused
on studies of cutaneous wound healing, which used human PnD.
Articles with insufficient data (insufficient group sizes, no
statistics, no controls, no adequate figures) were excluded.
After the screening process, we identified 79 relevant articles.
We observed a continuous increase in publications on the
application of PnD in animal models of cutaneous wound
healing during the last decade. The major part of these studies
was performed in Asia (China 41%, Iran 15%, rest of Asia 22%),
followed by the United States and Canada (11%), Europe (6%),
South America (4%) and Africa (Egypt 1%). From the relevant
articles, we extracted data concerning animal species (rodents,
large animals), diabetic status (diabetic or non-diabetic animals),
the type of wounds (full-thickness wounds, burns, radiation-
induced wounds, skin flaps, subcutaneous pockets), the source
and type of PnD (placenta, umbilical cord, fetal membranes, cells,
secretomes, tissue extracts), the method and dose of
administration (topical application, intradermal/subcutaneous
injection, intravenous or intraperitoneal injection,
subcutaneous implantation) and the use of delivery systems
(e.g., hydrogels, synthetic or natural biomaterials as carriers
for transplanted cells, extracts or secretomes). Data extraction
was performed to meet the populations, interventions,
comparators, outcomes and study designs (PICOS) criteria
(McKenzie et al., 2021).
PND USED FOR CUTANEOUS WOUND
HEALING IN PRECLINICAL STUDIES
Types, Dosage and Application Mode
of PnD
In the papers included in this review, PnD were applied in the
form of cells, cell secretomes (cell-derived conditioned media
(CM), cell-derived small extracellular vesicles (sEV), tissue
membranes and tissue extracts (Figure 1). Naming and
abbreviations of the PnD types in the reviewed studies varied
due to the authors’ discretion. To improve the comparability of
data, we harmonized terms according to the recently published
consensus nomenclature for perinatal tissues and cells (Silini
et al., 2020). For example, as there is no consensus on the zones of
Wharton’s jelly and on the experimental protocols for isolation of
the cells thereof, we have used the single term human umbilical
cord mesenchymal stromal cells (hUC-MSC), which comprises all
potential cell subpopulations. The types and combinations of the
PnD applied in these studies as well as the delivery systems are
outlined in detail in Tables 1–5. Overall, in 14 of 79 studies, two
different PnD types were addressed. The authors either compared
the effect of different PnD (e.g., cells vs. cell-derived CM, cells vs.
cell-derived sEV, cells vs. tissue), or two PnD types were applied
in combination (different cell types, cells and cell-derived CM,
cells and tissue).
To standardize the different dosages of PnD used in the
reviewed studies, the doses are presented as the number,
weight (μg), or volume (μl) of the specific PnD per wound
area (cm2), when the PnD were administered locally (topically,
intradermally/subcutaneously), or per body weight (kg) of an
animal, when PnD were applied systemically (intravenously or
intraperitoneally). To determine the dose of locally administered
PnD per cm2, we divided the quantity of applied PnD by the
wound area. In most of the studies, both the wound area and the
exact quantity of PnD were indicated.
Perinatal Cells
Perinatal cells were the most commonly used PnD type
in preclinical studies of cutaneous wound healing (49.5%)
(Table 1). Mostly, hUC-MSC were used (60.4%), followed by
hAMSC (12.5%) and MSC isolated from the whole placenta
(hPMSC, 8.3%). Cells were applied as suspensions injected
intradermally/subcutaneously or intravenously, topically by cell
spraying, or seeded on electrospun or biological scaffolds,
including the amniotic membrane. Cell therapy implemented
by administering cells to the bloodstream may lead to the
accumulation of injected cells in other organs such as the
lungs (Ankrum and Karp, 2010).
Perinatal cells were applied in doses ranging from 200 cells per
cm2 up to 8 million cells per cm2 (Figure 2A). The most
frequently applied dose was around 2 million cells per cm2
(mode  1.99 × 106/cm2, median  1 × 106/cm2). Regarding
mode of application, lower doses of cells were used for topical
application (median  0.6 × 106/cm2) than for subcutaneous
(median  1.78 × 106/cm2) and intradermal (median  3.54 × 106/
cm2) applications (Figure 2B). Mostly used dose for full-
thickness wound model was 1.99 × 106/cm2 (median  1.88 ×
106/cm2), while for the other wound models the doses were
usually less than 1 × 106/cm2 (median  0.12 × 106/cm2 for
burn wounds, 0.11 × 106/cm2 for radiation wounds, 0.22 × 106/
cm2 for skin flaps, and 0.1 × 106/cm2 for non-healing skin
lesions). The median cell doses for mice were higher (1.99 ×
106/cm2) than those for the rats (0.16 × 106/cm2). The systemic
doses were 25 × 106/kg and 29 × 106/kg when applied
intravenously, and 45 × 106/kg, when applied intraperitoneally
(Liu et al., 2014; Abd-Allah et al., 2015; Liu et al., 2016; Shi et al.,
2020). Moreover, few studies compared the effect of applying
different cell concentrations. Namely, in a full-thickness skin
wound model on rats, increasing the number of hAMSC injected
into the wound bed from 2 × 103/cm2 to 2 × 105 cells/cm2,
enhanced the wound healing results (Gao et al., 2020). On the
other hand, in a full-thickness burn wound model on pigs, low
doses, ranging from 200 to 40,000 cells per cm2, topically applied
in combination with a collagen-based scaffold, demonstrated
superior wound healing of full-thickness burn wounds,
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compared to higher doses (2 × 105/cm2 to 2 × 106/cm2) and
controls (Eylert et al., 2021). In a study that compared systemic
(intraperitoneal) and local (intradermal) application, the
intraperitoneal injections of hPMSC showed better results than
the local one, in terms of histological scores, expression of the
healing promoting factors, as well as the engraftment into the
wounded skin (Abd-Allah et al., 2015).
Perinatal Cell-Derived Conditioned Medium (CM)
Of the studies included in this review, 12.9% used perinatal cell-
derived CM (Table 2). The CM derived from hUC-MSC was the
most commonly used CM (58.3%). The CM is a medium collected
from cell cultures and contains various cell products released by
cells. These products may be proteins, non-coding RNAs, growth
factors, antioxidants, proteasomes, and extracellular vesicles, which
vary depending on the cell type and cell culture conditions
(Maguire, 2013). The advantage of using CM collected from
MSC to study regeneration lies in the ease of medium
availability, storing, freezing, drying, and transporting, as well as
in its lack of immunogenicity (Gunawardena et al., 2019).
CM was usually collected after 24, 48, and 72 h of cell
cultivation. It was mainly applied intradermally/
subcutaneously or topically and in combination with hydrogels
or as a cell spray. Doses of the CM used ranged from 7 to 354 μl/
cm2. No studies examined the effects of different CM dosages on
the efficacy of wound healing.
Several wound healing studies have investigated the combined
treatment of cell-derived CM and corresponding cells, or have
compared the efficacy of cell-derived CM versus cells alone.
While both CM and its corresponding perinatal cells, alone or
in combination, showed an increased rate of re-epithelization and
accelerated wound closure compared to control, no significant
difference in efficacy between the CM and the cells has been
demonstrated (Payne et al., 2010; Shohara et al., 2012; Shrestha
et al., 2013; Aguilera et al., 2014; Raj et al., 2019; Zhang et al.,
2020). Only rare studies used multiple doses of CM (Payne et al.,
2010; Sun et al., 2019). It was observed that frequent application
of CM achieved better results on wound healing than 2-fold
application (Payne et al., 2010).
Perinatal Cell-Derived Small Extracellular
Vesicles (sEV)
The least used PnD type (9.6%) were perinatal cell-derived EV
(Table 3). The cell secretome generally contains a mixture of
different EV subtypes, including exosomes, apoptotic bodies and
microparticles (Gangoda et al., 2015). The exosomes are the most
characterized and the smallest EV. They are of endosomal origin
with the size of 30–150 nm in diameter and carry many different
components, such as lipids, proteins, mRNAs, non-coding RNAs,
and even DNA derived from cells (reviewed in Rashed et al.
(2017)). It was first thought that exosomes only play a role in
removing unnecessary molecules from cells, but nowadays their
involvement in a plethora of different cell responses is
documented (Keller et al., 2006). According to their shape,
size, and marker expression (HSP70, CD9, CD63, CD81), the
EV described in the processed literature were characterized as
FIGURE 1 | The schematic presentation of the perinatal derivatives used in skin wound healing in preclinical studies. Cells: hUC-MSC, human umbilical cord
mesenchymal stromal cells; hAMSC, human amniotic membrane mesenchymal stromal cells; hPMSC, human placenta mesenchymal stromal cells; hUC-PVC, human
umbilical cord perivascular cells; hAEC, human amniotic membrane epithelial cells; hAFSC, human amniotic fluid stem cells; hAFC, human amniotic fluid cells;
Conditioned media (CM) derived from hUC-MSC, hAEC, hAMSC, hPMSC, hUC-PVC; Small extracellular vesicles (sEV) derived from hUC-MSC, hAMSC, hDMSC;
Tissues: hAM, human amniotic membrane; hAM/hCM, human amniotic/chorionic membrane; Tissue extracts derived from hAM, hP (human placenta), hP-ECM (human
placenta-derived extracellular matrix), hWJ-ECM (human Wharton’s jelly derived extracellular matrix).
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TABLE 1 | Application of perinatal cells in in vivo animal models of skin wound healing. Time points indicated in the “Outcome” column mean days (d), weeks (w) or hours (h)
after treatment.
Perinatal cells







hAEC showed higher engraftment, better keratinocyte-
transdifferentiation rates and acceleratedwound healing
(wound closure and re-epithelialization) than hASC (d28)
Jin et al. (2016)
Splint model
hAFC, hAFSC 1.59 ×
10^4 cells/cm2
Topical (polyester disks covered with
collagen)
Full-thickness, rat hAFC and hAFSC achieved accelerated wound closure,
epithelization, collagen fiber production, angiogenesis and
the disappearance of inflammatory cells compared to
controls without cells (d14, d17, d21)





hAFSC showed a better keratinocyte-
transdifferentiation and enhanced wound closure and
early-stage repair of skin damage than fibroblasts and
sham controls by creating a moderate inflammatory
microenvironment (d21)





hAFSC enhanced re-epithelialization and collagen III
contents and achieved lower numbers of
myofibroblasts and less fibrotic scarring than PBS
controls (best effects d14, after d21 no significance).







hAMSC had higher engraftment and keratinocyte-
transdifferentiation potential and induced a better
healing potential (increased wound closure, re-
epithelialization and cellularity) than ASC and
fibroblasts (d7, d10 and d14)




Topical (Matrigel or Matriderm) Full-thickness,
mouse
In both application forms, hAMSC promoted
neovascularization compared to control without cells.
Matriderm/hAMSC enhanced wound closure (d8).
Inhomogeneous distribution of Matrigel led to
inadequate wound closure
Tuca et al. (2016)
0.995 ×
10^6 cells/cm2




Matriderm and PCL/PLA were suitable as carriers for
hAMSC. 3 days in vitro culture of scaffolds with
hAMSCs without Matrigel before wound application is
recommended. PCL/PLA showed higher cell





Subcutaneous injection Skin flap, mouse hUC-MSC were mainly distributed in the subcutaneous
flap tissues and increased survival of the flap,
neovascularization and expression of bFGF and VEGF (d7)







SA/Col hydrogel + hUC-MSC accelerated wound closure,
formation of granulation, enhanced collagen deposition and
angiogenesis. Hydrogel promoted the survival of hUC-
MSC, enhanced growth factors secretion, and inhibited
inflammation (d7, d14)
Zhang et al. (2021)
0.11 ×
10^6 cells/cm2
Subcutaneous injection Radiation, rat hUC-MSC increased neovascularization and re-
epithelization (d14, d21, d28)





Compared to un-transduced hUC-MSC, c-Jun
overexpressing hUC-MSC accelerated wound
closure, enhanced angiogenesis and re-
epithelialization (d7, d10, d15, d17)









hUC-MSC accelerated angiogenesis compared to
ASC and control without cells (d7, d10) and provided
a suitable matrix for wound repair, without altering the





Topical (collagen membrane) Full-thickness,
mouse
HOXA4-overexpressing hUC-MSC differentiated into
epidermal cells and increased re-epithelialization of
wounds and thickness of the epidermis (d7, d14, d21)
He et al. (2015)
(Continued on following page)
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TABLE 1 | (Continued) Application of perinatal cells in in vivo animal models of skin wound healing. Time points indicated in the “Outcome” column mean days (d), weeks (w)
or hours (h) after treatment.
Perinatal cells
PnD cell type Dosage Application (carrier) Wound type,
animal
Outcome References




hUC-MSC promoted wound healing. Collagen-fibrin
carriers for hUC-MSC were more efficient in wound
healing than collagen membrane carriers (d5,
d10, d15)
Nan et al. (2015)
0.339 ×
10^6 cells/cm2
Topical (fibrin-based scaffold) Full-thickness,
mouse
Fibrin-based scaffolds with hUC-MSC healed slowly with
no scarring. Untreated wounds or wounds treated with
scaffoldswithout cells healed rapidly but disorderly, due to





Topical (PF-127/SAP hydrogel) Full-thickness,
mouse
PF-127/SAP hydrogel enhanced engraftment of hUC-
MSC in the dermis and facilitated dermis regeneration
(increase in thickness, collagen fibers, hair follicles),
angiogenesis and M2 macrophage formation (d8)
Deng et al. (2020)
1.77 ×
10^6 cells/cm2
Topical (collagen scaffold) Full-thickness,
diabetic mouse
Splint model
Combination of hUC-MSC therapy and hyperbaric
oxygen had a collaborative effect on wound-healing,






Topical (cell spray) Burn 3rd degree, rat hUC-MSC increased re-epithelialization compared to
control without cells. hUC-MSC were detected in the
burned areas at d7, d14, d21
Pourfath et al.
(2018)




hUC-MSC accelerated wound healing by activation of
the Wnt signaling pathway (d7, d14, d21)
Han et al. (2019)






Low dose hUC-MSC regenerated wounds most
efficaciously. Best effects were achieved by 40,000
cells/cm2 (accelerated epithelialization and
vascularization, reduced signs of scarring, fibrosis,
reduced numbers of macrophages compared to
controls (d28)











Topical (PVA hydrogel membrane) Non-healing skin
lesions, dog
hUC-MSC induced a significant progress in skin
regeneration with decreased extent of ulcerated areas





UC-MSC were detectable in the wound tissue (d16).
They improved wound healing by regulating
inflammation, trans-differentiation and providing growth
factors that promote angiogenesis, cell proliferation and
collagen deposition (d8, d16)
Shi et al. (2020)
25 ×
10^6 cells/kg
Intravenous injection Burn full-
thickness, rat
hUC-MSC were detectable in the wound tissue for 3
weeks. They accelerated wound healing (wound
closure, vascularization, collagen deposition) and
decreased inflammation (w2, w3, w6, w8)
Liu et al. (2014)
25 ×
10^6 cells/kg
Intravenous injection Burn full-
thickness, rat
hUC-MSC attenuated burn-induced excessive
inflammation via secretion of ant-inflammatory protein
TSG-6 which inhibits activation of P38 and JNK
signaling (6, 12, 24, 48 h)
Liu et al. (2016)
a) hUC-MSC-Fib Not specified Topical collagen-chitosan acellular
dermal matrix - tissue engineered
dermis (TED)
Full-thickness, pig me-VEGF-hUC-MSC-Fib improved the vascularization
of tissue-engineered dermis and induced a higher
wound healing than controls (me-hUC-MSC, empty
capsule and PBS-treated group) (w3)
Han et al. (2014)
b) me-VEGF-
hUC-MSC-Fib
a) hUC-MSC 5.09 ×
10^6 cells/cm2
(a-b) Intradermal injection Full-thickness,
mouse
Transplantation of celecoxib (anti-inflammatory drug)
-preconditioned hUC-MSC-End showed higher wound
healing potential than hUC-MSC and hUC-MSC-End (d7)
Kaushik and Das,
(2019)
b) hU-MSC-End Splint model
hPMSC 45 ×
10^6 cells/kg
Intraperitoneal and intradermal injection Full-thickness,
mouse
hPMSC enhanced wound healing through release of
proangiogenic factors and decreased
Abd-Allah et al.
(2015)
(Continued on following page)
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exosomes. However, the International Society for
Extracellular Vesicles in their position statement from
2018 (van Deun et al., 2017; Théry et al., 2018) urge
authors to use an operational term for EV subtypes unless
they can unequivocally prove their endosomal origin (by live
imaging techniques, for example). Therefore, according to
these recommendations, in this review we will refer to these
EV as small EV, or sEV. The sEV derived from perinatal cells
are a relatively new PnD type used for skin wound healing
since they first appeared in publications only a few years ago.
All included studies used sEV derived from MSC, most
commonly from hUC-MSC (77.8%).
The sEV were applied mostly by subcutaneous injection in
animals with burn or full-thickness wounds. The doses of sEV
were predominantly expressed as μg/cm2, except for one study
where the authors used the number of particles as a measure for
the sEV quantity (Bian et al., 2020). The doses were
comparatively uniform throughout the analyzed studies,
mainly using 100 to 156 μg/cm2 (Zhang et al., 2015a; Zhang
et al., 2015b; Zhang et al., 2016; Yang et al., 2019; Yang et al.,
2020; Zhao et al., 2020) and 318 μg/cm2 in one study (Liu et al.,
2021). There were no studies that compared different dosages
of sEV.
Perinatal cell-derived sEV showed similar (Zhang et al., 2015a)
or even better (Zhao et al., 2020) beneficial effects on wound
healing compared to perinatal cells. Gao et al. (2020) observed
that sEV overexpressing micro RNA (miR)-135a significantly
accelerated fibroblast cell migration by downregulating LATS2
levels to promote wound healing in rats making it the first
evidence of positive miRNA effect on this process. This was
TABLE 1 | (Continued) Application of perinatal cells in in vivo animal models of skin wound healing. Time points indicated in the “Outcome” column mean days (d), weeks (w)
or hours (h) after treatment.
Perinatal cells
PnD cell type Dosage Application (carrier) Wound type,
animal
Outcome References
proinflammatory cytokines. The intraperitoneal






hPMSC accelerated wound closure, increased
collagen deposition, granulation tissue and epidermis
thickness (d15). Wound healing was accelerated by
decrease of local pro-inflammatory cytokines TNF-α,
IL-6 and IL-1, increase of anti-inflammatory IL-10





PDGFR-β- hPMSC displayed a superior angiogenic
property and exerted enhanced therapeutic efficacy
on cutaneous wound healing compared to PDGFR-β
-negative hPMSC (d7, d14)




Topical (fibrin gel) Full-thickness,
mouse
hUC-PVC accelerated re-epithelization and dermal










hUC-PVC accelerated wound closure rate (faster re-
epithelization, more granulation tissue formation,
decreased scarring and increased neovascularization
than treatment without cells (d14, d21)
Milan et al. (2016)
a) hAEC-Ker a) 7,500 cells/cm2 Topical (plasma-based gel) Burn 2nd degree,
full-thickness
excision, rat
Scaffolds seeded with hUC-MSC-Fib and hAEC-
improved re-epithelization concurrent with reduced






a) hAMSC 0.6 ×
10^6 cells/cm2
(a-c) Topical (Matriderm) Full thickness,
mouse
hAMSC, hCP-MSC-bv and hUC-MSC induced faster
wound healing and vascularization compared to
controls without cell treatment (d8). hCP-EC co-
application did not further improve the advantageous
effects of MSC.





Abbreviations: bFGF, basic fibroblast growth factor; coI, collagen type I; hAEC, human amniotic membrane epithelial cells; hAEC-Ker, human amniotic membrane epithelial cells derived
keratinocytes; hAFC, human amniotic fluid cells; hAFSC, human amniotic fluid stem cells; hAMSC, human amniotic membrane mesenchymal stromal cells; hASC, human adipose
mesenchymal stromal cells; hCP-EC, human chorionic plate endothelial cells; hCP-MSC-bv, human chorionic plate mesenchymal stromal cells derived from blood vessels; hPMSC,
human placenta mesenchymal stromal cells; hUC-MSC, human umbilical cord mesenchymal stromal cells; hU-MSC-End, human umbilical cord mesenchymal stromal cells -endothelial
transdifferentiated; hUC-MSC-Fib, human umbilical cord mesenchymal stromal cells derived fibroblasts; hUC-PVC, human umbilical cord perivascular cells; me-VEGF- hUC-MSC-Fib,
microencapsulated VEGF-gene modified human umbilical cord mesenchymal stromal cells derived fibroblasts; PCL/PLA, Poly(caprolactone)/poly(l-lactide); PDGFA, platelet derived
growth factor A; PDGFR-β, platelet derived growth factor receptor β; PF-127/SAP, Pluronic F-127 hydrogel plus antioxidant sodium ascorbyl phosphate; PVA, polyvinyl alcohol; SA,
sodium alginate; TED, Topical collagen-chitosan acellular dermal matrix - tissue engineered dermis; TNF-α, tumor necrosis factor α; TSG-6, TNF-stimulated gene 6 protein; VEGF, vascular
endothelial cell growth factor; IL-1, IL-6, IL-10, interleukin-1, -6, -10.
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TABLE 2 | Application of perinatal cell-conditioned medium (CM) alone or compared to/combined with perinatal cells in in vivo animal models of skin wound healing. Time
points indicated in the “Dosage” and Outcome” columns mean days (d), weeks (w) or hours (h) of/after treatment.










hAEC-CM enhanced wound healing (closure,
tissue reorganization, replacement of skin
appendages), whereas CM+ ERK, JNK and
AKT- inhibitors impaired wound healing (d7,
d14). Control mice received PBS injection
Zhao et al.
(2016)
hPMSC-CM 31.85 μl (72 h) CM/cm2 Subcutaneous injection Burn degree
n.d., mouse
hPMSC were maintained in normoxic or
hypoxic conditions. Hypoxic CM reduced
scar formation, while there was no marked
difference between normoxic CM and
controls (normal medium) at d8
Du et al. (2016)
hUC-MSC-CM 50 μl (5 μg/ml) (48 h) CM/cm2
every 2nd d for 8w
Topical (hydrogel) Radiation, rat Hydrogel containing hUC-MSC-CM
accelerated wound closure, sebaceous gland
cell-like regeneration and angiogenesis
compared to EGF gel and negative control








Hydrogel containing CM of UC-MSC
transfected cells accelerated wound
contraction and promoted
neovascularization, skin-appendages,
epithelialization compared to control (PBS or




Perinatal cell-conditioned medium (CM) compared to/or combined with perinatal cells
PnD Dosage (CM harvesting time) Application (carrier) Wound type,
animal
Outcome References
a) hAMSC 2.546 × 10^6 cells/cm2 Subcutaneous injection Burn 2nd
degree, mouse
hAMSC and hAMSC-CM similarly
accelerated re-epithelialization and cell
proliferation compared to controls without
cells or CM (d7, d14, d21), increased
expression of CK19 and PCNA, inhibited heat
stress-induced apoptosis through activating
PI3K/AKT signaling pathway
Li et al. (2019)
b) hAMSC-CM 254.6 μl (48 h) CM/cm2
a) hAEC-CM I exp. 7 μl (72 h) CM/cm2 d1, d7 Topical (cell spray) Burn partial-
thickness,
guinea pig
hAEC, hAEC-CM, or the combination of both
improved epithelialization compared to
controls without cell or CM treatment (d7 –
d21). Frequent application of hAEC-CM for
every day achieved better results than 2-fold
application at d0 and d7
Payne et al.




II exp. 10 μl (72 h) CM/cm2 on
every 2nd d or 4th d or 7th d
for 3w




hUC-MSC and hUC-MSC-CM accelerated
wound closure and angiogenesis, with similar
effects at d10. CM induced better effects in
wound healing and higher expression of
PDGFß and KGF in wounds at d14
Shrestha et al.
(2013)b) hUC-MSC-CM 212.3 μl (24 h) CM/cm2
a) hUC-MSC or hU-
MSC-End
1.77 × 10^6 cells/cm2 (a-b) Intradermal injection Full-thickness,
mouse Splint
model
hUC-MSC and CM accelerated wound
closure, regeneration capacity and
neovascularization. hUC-MSC-End achieved
better cellular and paracrine effects than
hUC-MSC (d7, d12). Effects of cells were not





212.3 μl (48 h) CM/cm2




hUC-MSC and hUC-MSC-CM similarly
improved angiogenesis, re-epithelialization
and granulation (d14). Fibroblasts or PBS
served as controls
Zhang et al.
(2020)b) hUC-MSC-CM 298 μl (24 h) CM/cm2
(Continued on following page)
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an interesting aspect, because so far, different miRNAs (including
miR-135a) were mainly shown to impair wound healing (Bibby
et al., 2021).
Perinatal Tissues
Perinatal tissues (of which hAM predominate with 85.7%) were
applied in 15.1% of the included preclinical studies (Table 4). The
hAM serves as a potential wound dressing due to its high
biocompatibility, antimicrobial and anti-scarring properties. Its
anti-inflammatory properties have been attributed to the decrease
of pro-inflammatory cytokine expression (transforming growth
factor ß and interleukin 10). Furthermore, it produces B
defensins, elastase inhibitors, elastin, and lactoferrin with
antimicrobial effects, making it highly attractive in healing leg
ulcers (ElHeneidy et al., 2016). Decellularized or dehydrated
perinatal tissues were used as grafts or as support for perinatal
cells or cells of another origin and were applied topically. In cases
where the entire full-thickness or burn wound area was covered
with the hAM (Kim et al., 2009; Samadikuchaksaraei et al., 2016;
Motamed et al., 2017; Song et al., 2017; Farzamfar et al., 2018;
Gholipourmalekabadi et al., 2018; Kakabadze et al., 2019; Arasteh
et al., 2020; Nasiry et al., 2020), the wound areas are given instead
of dosages (Table 4). Also, in two studies where a proprietary
human amnion/chorion graft (EpiFix®) was implanted
subcutaneously, calculating the dosages was inapplicable (Koob
et al., 2013; Koob et al., 2014).
It was shown that combinations of cells and decellularized
hAM achieved better results on wound healing than either cells or
hAM alone (Kim et al., 2009; Sabapathy et al., 2014;
Samadikuchaksaraei et al., 2016; Motamed et al., 2017;
Farzamfar et al., 2018; Gholipourmalekabadi et al., 2018;
Kakabadze et al., 2019; Hashemi et al., 2020).
Perinatal Tissue Extracts
Of the included studies, 12.9% used perinatal tissue extracts
(Table 5). The most frequently used tissue extract was hAM
extract (41.7%). Tissue extracts are usually obtained by tissue lysis
and centrifugation, hence they do not contain cells, but are rich in
an array of proteins, minerals, amino acids, and steroid hormones
(Datta and Bhattacharyy, 2012). Tissue extracts possess anti-
inflammatory, antioxidant, and cytoprotective properties and
stimulate proliferation and reparative processes similar to their
tissues of origin (reviewed in Pogozhykh et al. (2018)).
Perinatal tissue extracts (some of which were prepared as a
powder) were applied topically or by subcutaneous injection,
mostly on full-thickness skin wounds, and once on either a
burn wound or a skin flap model, respectively. The amount of
the extracts used was usually expressed in μg of lyophilized powder
or, in some cases, in μl of proprietary human placental extracts. The
doses ranged from 1 μg to 83.3 μg/cm2. In two studies that
compared the application of lower and higher doses of perinatal
tissue extracts, higher doses performed better in terms of wound
healing rate, reduced inflammation (Momeni et al., 2018), and skin
flap survival (Kwon et al., 2019). Acellular umbilical cord-derived
Wharton’s jelly extract (hWJ-ECM) was applied with Matrigel or
in the form of a spongy scaffold in doses of 353.7 and 450 μl/cm2,
respectively, providing enhanced wound closure and re-
epithelization (Bakhtyar et al., 2017; Beiki et al., 2017). In one
TABLE 2 | (Continued) Application of perinatal cell-conditioned medium (CM) alone or compared to/combined with perinatal cells in in vivo animal models of skin wound
healing. Time points indicated in the “Dosage” and Outcome” columns mean days (d), weeks (w) or hours (h) of/after treatment.






a) hUC-MSC 1.99 × 10^6 cells/cm2 3.54 ×
10^6 cells/cm2 199 μl (72 h)






hUC-MSC and hUC-MSC-CM applied by AV/
PCL carrier or subcutaneous injection





medium (d7, d14, d28)
Raj et al. (2019)
b) hUC-MSC-CM






alginate achieved faster wound healing than










hUC-PVC and hUC-PVC-CM accelerated
wound closure and healing (collagen
deposition and angiogenesis) compared to
fibroblasts and fibroblast-CM (d4, d7, d14).
Effects of cells were not directly compared to
the effects of CM.
Shohara et al.
(2012)b) hUC-PVC- CM 354 μl (48 h) CM/cm2
Abbreviations AV/PCL, Aloe vera/po lycaprolactone; hAEC, human amniotic membrane epithelial cells; hAMSC, human amniotic membrane mesenchymal stromal cells; hPMSC, human placenta
mesenchymal stromal cells; hUC-MSC, human umbilical cord mesenchymal stromal cells; hU-MSC-End, human umbilical cord mesenchymal stromal cells-endothelial transdifferentiated; hUC-PVC,
human umbilical cord perivascular cells; CM, conditioned medium derived from hAEC, hAMSC, hPMSC, hUC-MSC, hUC-MSC-End, hUC-PVC; SA, sodium alginate.
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study, hybrid extracellular matrix sponges containing human
placenta-derived extracellular matrix were applied within the
wound area, but no volume or other quantitative value of the
applied matrix was specified (Rameshbabu et al., 2018).
It was shown that amnion-derived hydrogel and amnion
powder achieved better results on wound healing than
AmnioGraft® (Murphy et al., 2020). The combination of the
human placental extract with autologous bone marrow MSC
TABLE 3 | Application of perinatal cell-derived small extracellular vesicles (sEV) alone or compared to perinatal cells in in vivo animal models of skin wound healing. Time
points indicated in the “Dosage” and “Outcome” columns mean days (d) or weeks (w) of/after treatment.
Perinatal cell-derived small extracellular vesicles (sEV)





100 μg/cm2 Subcutaneous injection Burn 2nd
degree, rat
hUC-MSC-sEV enhanced re-epithelization and
promoted self-regulation of Wnt/β-catenin signaling
during the tissue remodeling period of cutaneous
regeneration compared to PBS control (w2, w4)
Zhang et al.
(2016)
100 μg/cm2 Subcutaneous injection Burn 2nd
degree, rat
hUC-MSC-sEV promoted re-epithelization and
angiogenesis compared to controls (PBS, fibroblast-
Ex, d7). Proangiogenic effects were inhibited by
interference of Wnt4 expression in hUC-MSC- sEV.
Zhang et al.
(2015b)
318 μg/cm2 Subcutaneous injection Burn 2nd
degree, rat
hUC-MSC-sEV accelerated wound closure and
angiogenesis compared to control (PBS, d13).
Overexpression of Ang-2 in hUC-MSC-sEV further
enhanced therapeutic effects. Knockdown of Ang-2 in
hUC-MSC-sEV abrogated these effects
(Liu et al., 2020)
127 µg/cm2 Subcutaneous injection Burn 2nd degree,
mouse
hUC-MSC- sEV treated with blue light (455 nm)








hUC-MSC-sEV -hydrogel and hUC-MSC- sEV -PBS
accelerated the wound closure rate and
vascularization compared to controls (gel, PBS). hUC-
MSC- sEV -hydrogel achieved better effects than
hUC-MSC- sEV -PBS (d7, d10, d14)
Yang et al.
(2020)
hDMSC-sEV 2.6 × 10^10 particles/




hDMSC-sEV accelerated wound closure and collagen
deposition compared to PBS controls (d14, d21)
Bian et al.
(2020)
Perinatal cell-derived small extracellular vesicles (sEV) compared to perinatal cells
PnD Dosage Application (carrier) Wound type,
animal
Outcome References
a) hAMSC 2,222; 22,222; or
222,222 cells/cm2





Full-thickness, rat hAMSC and hAMSC-sEV enhanced wound closure
and epidermalization. hAMSC-miR-135a-sEV
induced faster wound healing than hAMSC-sEV (d5).








a) hUC-MSC 1.56 × 10^6 cells/cm2 (a-b) Subcutaneous injection Full-thickness,
mouse
hUC-MSC-sEV attenuated full-thickness skin wounds
by enhancing epidermal re-epithelialization and








100 μg sEV/cm2 Subcutaneous injection Burn 2nd
degree, rat
hUC-MSC and hUC-MSC-sEV similarly accelerated
re-epithelialization and increased expression of CK19,
PCNA, and collagen I compared to control (PBS,
fibroblast, Fibroblast-sEV, d7, d14) viaWnt4 pathway.
hUC-MSC-sEV reduced heat stress-induced
apoptosis via activation of AKT pathway
Zhang et al.
(2015a)
b) hUC-MSC 0.5 × 10^6 cells/cm2
Abbreviations; hAMSC, human amniotic membrane mesenchymal stromal cells; hAMSC-miR-135a, human amniotic membrane mesenchymal stromal cells overexpressing miR-135a;
hDMSC, human decidua mesenchymal stromal cells; hUC-MSC, human umbilical cord mesenchymal stromal cells; sEV, small extracellular vesicles derived from hAMSC, hDMSC, hUC-
MSC; miR-135a-sEV, sEV overexpressing microRNA135a.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org September 2021 | Volume 9 | Article 74285810
Pichlsberger et al. Perinatal Derivatives and Wound Healing
TABLE 4 | Application of perinatal tissues alone or compared to/combined with perinatal cells or cells of non-perinatal origin in in vivo animal models of skin wound healing.





Wound type, animal Outcome References
a) hAM wa 0.2 cm2 Topical Full-thickness, mouse
Splint model
hAM-silk fibroin scaffolds achieved
better epidermal and dermal
regeneration than hAM-treated and
untreated wounds (d30)
Arasteh et al. (2020)
b) hAM + silk fibroin
a) hAM wa 1.77 cm2 Topical Full-thickness, diabetic
rat, non-diabetic
control rat
hAM-S seemed to have better effects
on the healing of diabetic wounds than
hAM (d7, d14, d21)
Nasiry et al. (2020)
b) hAM-S Splint model
hAM wa 1.69 cm2 Topical Full-thickness, rat hAM promoted wound closure (d3, d5,
d7), and enhanced VEGF and α- SMA
expression (d7). Reduced TGF-β1
expression at an early stage (d3)
alleviated wound inflammation,
promoted tissue regeneration and
relieved scar formation compared to
PBS treated wounds









hAM/chorion implants recruited more
mesenchymal progenitor cells to the
site of implantation compared to normal
skin and the sham implant site (d7)









hAM/chorion implants displayed a
steady increase in microvessels
approaching that of healthy and healing
skin (d28)
Koob et al. (2014)
Perinatal tissues compared to/or combined with perinatal cells
PnD Dosage Application Wound type, animal Outcome References




Full-thickness, mouse Combination of hUC-MSC and hAM
achieved better wound healing (reduced
scar formation with hair growth and
improved biomechanical properties of
regenerated skin) than hUC-MSC alone
(d14) and untreated wounds
Sabapathy et al. (2014)
b) hUC-MSC+ hAM b) Topical
c) hAM





Burn 3rd degree, rat hUC-MSC/hAM combination induced
better wound healing (re-
epithelialization, formation of
granulation tissue, and hemorrhage)
than hAM and hUC-MSC alone (d14)
Hashemi et al. (2020)
b) hAM
c) hUC-MSC+hAM
Perinatal tissues combined with cells of non-perinatal origin
PnD Carrier of the
topical PnD
application
Wound type, animal Outcome References
a) hAM wa 11–18 cm2 0.5 ×
10^6 cells/cm2
Topical Burn 3rd degree, rat hAM seeded with fibroblasts or with
ASC similarly showed better wound
healing than hAM-only and control
(Vaseline gauze) (d7, d14, d20,
d28, d40)
Motamed et al. (2017)
b) hAM+hFib
c) hAM+hASC
a) hAM wa 0.79 cm2
10,000 cells/cm2




Silk fibroin accelerated wound healing
compared to hAM only. hAM/silk
fibroin+hASC achieved better effects
Gholipourmalekabadi
et al. (2018)b) hAM/silk fibroin
c) hAM/silk fibroin+hASC
(Continued on following page)
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achieved better results on wound healing than placental extract
applied without cells (Akela et al., 2013).
In vitro Characterization and Functional
Testing of PnD Before Their Application in
Preclinical Studies
The evaluation of the in vitro characterization (Figure 3A)
displayed the sEV as the most in vitro characterized PnD, as
they were properly characterized in all included studies. The
methods used for the characterization were: transmission
electron microscopy to observe their morphology (100%),
Western blot to determine the expression of exosome markers
(89%), and nanoparticle tracking analysis to measure the size of
sEV (89%). The reputable characterization of sEV is most probably
due to the exact guidelines for isolation and characterization (van
Deun et al., 2017; Théry et al., 2018). Encouraging the scientific
community to properly perform exosome characterization has
proven to be a good practice that provides transparency to the
studies, and should also be considered in other fields. Cells were
also fairly well characterized in vitro (84.8%). The predominant
methods were: flow cytometry to identify the presence of the cell
surfacemarkers (87.2%), assessment of the differentiation potential
into multiple lineages to confirm their stemness (50%), and bright
field microscopy to verify morphological characteristics (35.9%).
Of perinatal cell-derived CM, 83.3% were characterized in vitro.
CM was biochemically analyzed in just one of the studies
(Sabzevari et al., 2020), however, we further defined CM as
“in vitro characterized” also when the corresponding cells were
identified and characterized at the molecular and morphological
levels. Perinatal tissues were in vitro characterized with a
proportion of 50%; this group also includes commercially
available perinatal tissues (71.4%).
We considered commercially obtained perinatal tissues as
“in vitro characterized,” since the vendors clearly describe
them. As the most commonly used perinatal tissue is the
hAM, we assume that the poor percentage of the in vitro
characterization is due to the fact that the hAM has been
characterized and tested many times before. Further,
identification and preparation of the hAM are unambiguous
and straightforward (Jerman et al., 2014; Poženel et al., 2019;
Jerman et al., 2020; Ramuta et al., 2020; Weidinger et al., 2020),
whereas cells and cell-derived secretomes or sEV require precise
characterization. Since the vast majority of the researchers
isolated cells from the perinatal tissues by themselves,
adequate characterization is mandatory to assure that a pure
cell population has been isolated. The least in vitro characterized
PnD were perinatal tissue extracts (41.7%).
TABLE 4 | (Continued) Application of perinatal tissues alone or compared to/combined with perinatal cells or cells of non-perinatal origin in in vivo animal models of skin





Wound type, animal Outcome References
than hAM/silk fibroin without ASC (d7,
d14, d28) and reduced post burn scars




wa 5.06 cm2 Topical Full-thickness, rabbit hAM grafts loaded with autologous and
allologous BM-MSC similarly
accelerated wound closure compared
to hAM grafts with injected BM-MSC
(d7, d12, d15)
Kim et al. (2009)
88,888 cells/cm2
on hAM
3.02 × 10^6 cells/
cm2 i.d
a) hAM wa 2 cm2 number of
cells per cm2 Not
specified
Topical Radiation followed by
full-thickness, rat
hAM+BM-MSC and hAM+ freeze-dried
BM-MSC similarly accelerated wound
closure compared to hAM only.
Inflammation and exudations were
absent when hAM was used in contrast
to non-treated wounds (Observation
period 90 days)
Kakabadze et al. (2019)
b) hAM+BM-MSC






wa 4 cm2 0.1 ×
10^6 cells/cm2
Topical Full-thickness, rat All treatments resulted in similar wound
closure (d7-d21). TGF-β3 expressing











a) hAM wa 2.25 cm2 Topical Full-thickness, rat Men-MSC+hAM improved wound
closure, angiogenesis and re-epithelization
compared to hAM-only (d14)
Farzamfar et al. (2018)
b) hAM+ Men-MSC 30,000 cells/cm2
Abbreviations: α-SMA, alpha-smooth muscle actin; BM-MSC, bone-marrow mesenchymal stromal cells; hAM, human amniotic membrane; hAM-S, bioengineered 3D hAM-scaffold;
hASC, human adipose mesenchymal stromal cells; hFib, human fibroblasts; hUC-MSC, human umbilical cord mesenchymal stromal cells; Men-MSC, menstrual blood mesenchymal
stromal cells; TGF-β1, transforming growth factor beta-1; VEGF, vascular endothelial cell growth factor; wa, wound area covered by tissue membranes.
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TABLE 5 | Application of perinatal tissue extract alone or compared to/combined with with perinatal tissue or cells of non-perinatal origin in in vivo animal models of skin







hAM extract 83.3 μg extract/cm2 a) Topical Burn 1st
degree, rat
hAM+chitosan-gel increased cutaneous
regeneration (granulation tissue, fibroblast
proliferation, vascularization) compared to controls
(PBS, gel) (d15, d25, d31). High concentrated
hAM extract (1 mg/ml) achieved better effects
than low concentrated hAM extract (0.1 mg/ml)
Momeni et al.
(2018)8.33 μg extract/cm2 b) Topical (chitosan
hydrogel)
hAM extract 100 μg/ml wound dressing
(applied volume not spec.)
Topical (PVA/SA gel) Full-
thickness, rat
hAM+PVA/SA-gel accelerated wound closure,
increased re-epithelization, granulation tissue
areas, neovascularization, collagen proliferation
and reduced number of inflammatory cells
compared to Medifoam™ hydrogel or the
control (sterile gauze) (d6, d9, d12)
Choi et al. (2014)
hP extract 3.98 µl extract/cm2 Subcutaneous injection Full-
thickness,
mouse
hP extract accelerated wound healing (d3-d9)
TGF-β increased in the early phase of wound
healing (d6) and VEGF in the late phase (d14)
compared to PBS control
Hong et al.
(2010)
3.33 μl extract/cm2/d Subcutaneous injection
or Intraperitoneal
injection
Skin flap, rat hP extract enhanced flap survival,
angiogenesis, reduced necrotic areas, induced
antioxidative response and inhibited apoptosis
compared to PBS control. Daily application
(d0-d6) of low dose localized or systemic hP
injections or high dose. Systemic high dose HP
injections showed the best effects. (d7)
Kwon et al.
(2019)0.45 and 1.35 ml/kg/d every
day for 7 days
a) hP extract a) 35 μg/cm2 Subcutaneous injection Full-
thickness, rat
hP and placental laminin accelerated wound
closure compared to PBS controls (d5, d7, d9)
Mukherjee et al.
(2020)b) Placental laminin b) 11 μg/cm2
a) hAM powder 2 μg hAM/cm2 Topical Burn 2nd
degree, rat
hAM powder, AV, and hAM+AV accelerated
wound healing compared to untreated
wounds (d24)
Rahman et al.
(2019)b) hAM powder+AV 1 μg hAM + 1 μg AV/cm2





hAM-hyaluronic acid hydrogel accelerated
wound closure, wound re-epithelialization,
vascularization compared to controls
(hydrogel, untreated). Hydrogel ± hAM
counteracted wound contracture in contrast
to untreated wounds (d7, d14)
Murphy et al.
(2017)




hP-ECM-silk fibroin scaffolds acceleratedwound
closure (pronounced angiogenesis, enhanced
granulation tissue formation, early re-
epithelialization) compared to controls (collagen-
silk-fibroin scaffolds, sham) (d7, d14, d21)
Rameshbabu
et al. (2018)





WJ-ECM scaffolds accelerated wound
closing and re-epithelization compared to
wounds without scaffolds (d7, d12) and
counteract wound contracture (d18)
Beiki et al. (2017)
hWJ-ECM 353.7 μl/cm2 Topical (Matrigel) Full-
thickness,
mouse
Acellular hUC-WJ+Matrigel enhanced wound
closure and augmented the differentiation of
fibroblasts into myofibroblasts compared to
control (DMEM-Matrigel) (d5, d7)
Bakhtyar et al.
(2017)
Perinatal tissue extracts compared to perinatal tissue
PnD Dosage Application (carrier) Wound type,
animal
Outcome References
(Continued on following page)
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In addition to in vitro characterization, in vitro functional tests
were performed (Figure 3B). The differentiation and proliferation
assays, scratch wound assay, and cytotoxicity assay were the most
prevalently used to evaluate the effect of different PnD on cell
cultures in vitro. The in vitro functional tests are usually quick and
performed under controlled conditions. Compared to the animal
models, they certainly lack the complexity of the native tissue.
Nevertheless, monitoring the specificmechanisms in vitro is a good
indicator of how the tested materials affect the biological processes
in vivo. Among the PnD used in the preclinical studies of skin
wound healing, 77.8% of the perinatal cell-derived sEV were
functionally tested in vitro. Moreover, 58.3% of included studies
performed functional tests in vitro on perinatal tissue extracts, and
half of the studies functionally tested the perinatal cell-derived CM.
On the other hand, despite being the most frequently used PnD in
skin wound healing, only 41.3% of the perinatal cells were
subjected to functional in vitro assays before their application in
preclinical studies. The least in vitro tested PnD were perinatal
tissues (21.3%).
ANIMAL MODELS OF CUTANEOUS
WOUND HEALING
Animal models span various wound types, multiple animal
species, and strategic scientific approaches for wound
TABLE 5 | (Continued) Application of perinatal tissue extract alone or compared to/combined with with perinatal tissue or cells of non-perinatal origin in in vivo animal models







a) hAM powder Not specified Topical Full-
thickness, pig
Amnion+hydrogel and amnion powder
accelerated wound healing compared to
AmniograftR > hydrogel only > untreated
wounds > graft jacket. The treatment with
graft jacket-only led to the worst healing (most






Perinatal tissue extracts combined with cells of non-perinatal origin





Concentration of hPE not
specified (commercial




hP-E+ BMSC achieved better results on
wound healing (accelerated wound closure,
earlier disappearance of inflammatory
reaction, better epithelialization,
neovascularisation, and collagen formation
than the other groups (d7, d14, d21, d30)
Akela et al.
(2013)




Abbreviations: AV, aloe vera; BM-MSC, bonemarrowmesenchymal stromal cells; hAM, human amniotic membrane; hPE, human placenta extract; hP-ECM, human placenta extracellular
matrix; hUC-WJ-ECM, human umbilical cord Wharton´s jelly extracellular matrix; PVA, polyvinyl alcohol; SA, sodium alginate.
FIGURE 2 | (A)Correlation of applied PnD cell type versus cell number/cm2 on a logarithmic scale (Log10). hUC-MSC, human umbilical cord mesenchymal stromal
cells; hAMSC, human amniotic membrane mesenchymal stromal cells; hPMSC, human placenta mesenchymal stromal cells; hAFC, human amniotic fluid cells; hAFSC,
human amniotic fluid cells; hUC-PVC, human umbilical cord perivascular cells; hAEC, human amniotic membrane epithelial cells. (B) Correlation of cell doses with the
mode of administration. Lines represent median values.
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treatment. According to most common problems in wound
healing in humans, such as full-thickness wounds, chronic
ulcers caused by diabetes, poorly healing wounds after
radiation, or severe burn injuries, the animal models are
adapted to these conditions as well as possible.
The herein described animal models dealt with full-thickness
wounds (53 studies), burn wounds (18 studies), radiation wounds
(three studies), skin flaps (two studies), and subcutaneous pockets
(two studies). One case report described the application of PnD
on non-healing skin lesions (Figure 4; Tables 1–5).
FIGURE 3 | (A) The schematic presentation of the PnD characterization and (B) verification in vitro. The sEV derived from perinatal MSC are overall the most
characterized and in vitro tested PnD used in skin wound healing in preclinical studies. Conversely, the least characterized and in vitro tested PnD are the perinatal
tissues. The commercially available PnD or the PnD that have been described in the previous studies by the same authors, were defined as characterized in vitro,
although the exact data were not provided in the actual study.
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Wound Models
Full-Thickness Wound Models
In full-thickness wounds, all skin layers including the
subcutaneous tissue, are removed. Full-thickness wounds were
inflicted mainly by biopsy punches or by scalpels and surgical
scissors. In addition to healthy animals, this wound type has also
been applied to diabetic animals to mimic impaired healing
conditions and chronic wounds.
Diabetic Wound Models
Diabetes is a major health care problem. A diabetes-related
foot ulcer is one of the most challenging complications in the
treatment of diabetic patients. More than half of diabetic
ulcers become infected and lead to amputation in 20% of
cases. (Armstrong et al., 2017). Thus, several studies use
diabetic mouse and rat models to develop new strategies
for treatment.
Experimental type 1 diabetes can be studied on a genetic
non-obese diabetic mouse line or on mice/rats treated with
streptozotocin, which destroys pancreatic beta cells. The
advantage of diabetes induced by streptozotocin injection
is that there is no limitation to a particular mouse or rat
strain. Two studies used the non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mice, which
have a metabolic state similar to type 1 diabetes ((Jin
et al., 2016) and (Kim et al., 2012)). One study used a
streptozotocin-induced C57BL/6J mouse (Zhang et al., 2020).
Four studies used diabetic rat models on streptozotocin-induced
SD rats (Han et al., 2019; Shi et al., 2020; Yang et al., 2020; Yue et al.,
2020). One further study used streptozotocin-induced Wistar rats
(Milan et al., 2016).
Type 2 diabetes can be induced by a high-fat diet or genetically
in the leptin-deficient mouse line (Boyko et al., 2017). Four
studies (Shrestha et al., 2013; Peña-Villalobos et al., 2018; Raj
et al., 2019; Bian et al., 2020) used leptin-deficient db/db mice as a
diabetes type 2 model. Affected mice show morbid obesity,
chronic hyperglycemia, pancreatic beta-cell atrophy, and
hypoinsulinemia. They are polyphagic, polydipsic, and
polyuric, similar to diabetic type 2 patients. This mouse line is
recommended for wound healing models2.
Wang et al. (2016) used the Goto-Kakizaki rats as a non-obese
model of type 2 diabetes with metabolic, hormonal, and vascular
disorders similar to human diabetes.
Burn Injury Wound Models
Burn wounds can be created by scald, contact, chemical or electrical
combustion. The severity of the burn wound (Supplementary Table
S1) depends on the temperature and exposure time of the heat
source to the skin, as well as on the skin thickness.
Except for the study on pigs (Eylert et al., 2021), all burn injury
wound models of the reviewed studies were performed on rodents
(primarily mice and rats, with one study was performed on guinea
pigs). Burn wounds were created by scalding with hot water
(70°C–94°C) for 6–100 s (Liu et al., 2014; Zhang et al., 2015a;
FIGURE 4 | Distribution of wound types and applied PnD types.
2https://www.criver.com/products-services/find-model/jax-dbdb-mice?
region=3616/
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Zhang et al., 2015b; Du et al., 2016; Liu et al., 2016; Zhang et al., 2016;
Momeni et al., 2018; Li et al., 2019; Yang et al., 2019; Liu et al., 2021)
or by a heated brass rod or aluminum devices (100–105°C, for
5–30 s), where wound size and shape depend on the size and shape of
the instrument used (Motamed et al., 2017; Gholipourmalekabadi
et al., 2018; Pourfath et al., 2018;Mahmood et al., 2019; Rahman et al.,
2019; Hashemi et al., 2020). As wounding by the brass bar technique
leads to scab formation, the developed necrosis was usually excised
12–48 h before application of PnD.
In most studies, severe burn injuries of 2nd or 3rd degree were
performed. Some authors described the injury as “full-thickness
burn injuries” which would correspond to at least category IIa
according to the severity score. In cases with extensive wounds, an
injection of balanced salt solution was given to prevent shock.
Uniformpartial-thickness burns cannot be reproducibly created
inmice and rats due to their estrous hair cycle (Robson et al., 1980),
and superficial burns in pigs heal too quickly, because the porcine
epidermis is 2-fold thicker than the human equivalent (Hammond,
2000). Thus, a higher temperature is needed to create severe burn
wounds in pigs. (Eylert et al., 2021) used a heated aluminum device
(200°C) for 20s and digital force gauge and histologically confirmed
full-thickness burn wounds 48 h post-burn via punch-biopsy.
Payne et al. (2010) studied partial-thickness burn wounds on
guinea pigs, which do not have hair cycles and are therefore the
more satisfactory model to evaluate this wound type. Only one
study investigated superficial first-degree burn wounds on rats
(Momeni et al., 2018).
Some authors described the percentage of the total body
surface area (%TBSA) affected by a burn. 10% TBSA wounds
were performed on guinea pigs (Payne et al., 2010), 30% TBSA
and 50% TBSA on rats (Liu et al., 2014; Liu et al., 2016).
Due to a large number of different parameters such as wound
size, heat exposure time, application of brass bar or water,
inconsistent use of the severity score, and different treatments
and application modes with PnD, a comparison of investigated
experiments is not possible.
Radiation-Induced Wound Models
Radiation dermatitis is a common side effect of radiotherapy.
Many of the radiation-induced skin changes are minor and
reversible. Nevertheless, when acute changes do not resolve,
skin ulcers, fibrosis, or necrosis of underlying structures may
occur. Disruption of the epithelial basement membrane and
breakdown of the barrier function substantially increase the
risk for these injuries (Hymes et al., 2006). The severity grade
is shown in Supplementary Table S2 according to the
Classification of radiation dermatitis from the National Cancer
Institute (Hymes et al., 2006).
In the studies reviewed, 3rd or 4th-grade radiation wounds were
created in rats (Liu et al., 2014; Kakabadze et al., 2019; Sun et al.,
2019), respectively. Radiation dose and exposure time varied
between the different studies. Liu et al. (2014) administered a
dose of 45 Gy for 7.5 min per animal, Sun et al. (2019)
administered 40 Gy for 25min and Kakabadze et al. (2019)
used a dose of 60 Gy without specifying of the radiation duration.
Sun et al. (2019) topically applied Hydrogel containing hUC-
MSC-CM every second day after radiation for 8 weeks. PnD
treatment accelerated wound closure, sebaceous gland
regeneration, and angiogenesis compared to EGF application
and negative control (weeks 2, 4, 6, 8).
Liu et al. (2014) created ulcers and Kakabadze et al. (2019)
excised the radiation areas 3 weeks post-radiation to simulate a
chronic radiation injury before starting the treatment with PnD.
Subcutaneous injection of hUC-MSC increased
neovascularization and re-epithelization, days 14, 21, 28 after
treatment (Liu et al., 2018). Topical application of decellularized
hAM seeded with BM-MSC (Kakabadze et al., 2019) accelerated
wound closure compared to decellularized hAM. Inflammation
and exudations were absent when the decellularized hAM was
used (observation period 90 days).
Due to different intervals of evaluation, only days 7 and 14
could be used for a comparison, whereby the comparison is
limited by different doses of radiation, different surgical
interventions post-radiation, and different time points of
application of the various PnD. In all investigated works,
wounds treated with PnD showed a significantly accelerated
wound healing on day 14 compared to control groups.
Due to the limited data and varying methods, a clear
recommendation for the optimal treatment method
concerning the application of PnD for the healing of
radiation-induced wounds is not possible.
Skin Flap Models
A skin flap is a full-thickness mass of skin containing superficial
fascia, transplanted from a donor site to a recipient site with an
intact blood supply. Skin flap surgery is a common procedure in
reconstructive surgery. In this field, surgeons often struggle with
ischemia-associated complications such as tissue necrosis or
wound breakdown (Schmauss et al., 2018). Flap models in
rodents are versatile and have a long tradition in experimental
surgery. In studies included in this review, two types of skin flaps
were performed: the epigastric ischemic skin flap (EIF) and the
McFarlane flap.
The EIF is an axial skin flap, designed at the pedicled
superficial inferior epigastric vessels. The skin flap is lifted
from its remote end, and the vascular pedicle gets clamped for
a specific time to induce flap ischemia. Leng et al. (Leng et al.,
2012) performed the EIF on mice at a size of 3 × 6 cm and
clamped the respective blood vessels for 6 h. Then, the flap was
opened to remove the clamps and to enable flap reperfusion. The
flap was sutured in situ and hUC-MSC were subcutaneously
injected into the flap at 10 distributed points. After 7 days, the
survival area of the flap was evaluated concerning the gross
appearance, necrosis, and vascularization. hUC-MSC were
detectable in the flap tissues and increased the survival of the
flap, neovascularization, and expression of bFGF and VEGF
compared to controls without cell treatment.
TheMcFarlane flap model is characterized by a cranially based
and randomly perfused dorsal skin flap, which is elevated beneath
the musculus panniculus carnosus. It has a defined width-to-
length ratio to ensure a predictable rate of necrosis. Perforating
blood vessels were electrically cauterized to ensure a completely
random vascular pattern. Kwon et al. (2019) performed this
model on rats with a flap size of 3 × 10 cm to investigate
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therapeutical effects of human placenta extract (hP-E) applied by
subcutaneous or intraperitoneal injections. hP-E enhanced flap
survival, angiogenesis, reduced necrotic areas, induced
antioxidative response, and inhibited apoptosis compared to
phosphate-buffered solution (PBS) control. Daily application
(d0-d6) of low dose (10 mg/kg/d) localized or systemic hP-E
injections or high dose (40 mg/kg/d) systemic hP-E injections
showed the best effects of high dose administration (d7).
Although data on using PnD in skin flap models are rare, both
approaches showed promising results.
Subcutaneous Pocket Model
Koob et al. (2013), Koob et al. (2014) created subcutaneous
pockets in mice and implanted commercially available
dehydrated human amnion/chorion-tissue allografts (PurionR)
at a size of 5 × 5 mm to investigate their biological and angiogenic
properties. hAM/chorion implants recruited more mesenchymal
progenitor cells to the site of implantation compared to uninjured
skin and the sham implant site (day 7). In addition, implants
displayed a steady increase in microvessels approaching that of
healthy and healing skin after 28 days.
Animal Species Used for Cutaneous Wound
Healing Models
Rodents
The vast majority of animal wound models (92%) were performed
on rodents, with 40 and 32 studies performed on mice and rats,
respectively. Only one study was performed on guinea pigs. Rodents
are easy to handle and inexpensive with respect to costs for food,
medication, and wound dressings. They are simple to house and
have a short life cycle. Generally, smaller wounds were created on
mice and rats than on larger animals, which helps to reduce the
quantity of applied PnD material. However, rodents’ wounds close
due to the contraction of the musculus panniculus carnosus, a thin
layer of skeletal muscle located in subcutaneous tissue, which is
virtually non-existent in most regions of the human body (Zomer
and Trentin, 2018). This physiological difference creates difficulties
in replicating the wound closure processes of human skin, which
should be considered. For long-time experiments on full-thickness
wounds, anti-contractive tools should be chosen (described in the
chapter Wound Healing in Rodents).
Mouse Strains Used in Wound Healing Studies
The C57BL/6 mouse was the most commonly used strain in the
analyzed studies (Figure 5A). It is a general-purpose strain.
Some of its characteristics are a high susceptibility to diet-
induced obesity, diabetes II, and atherosclerosis. It has a
nearly black coat, is easy to breed, and is robust. However, it
tends to bite, and male mice remove hair from their cage mates
(Sarna, 2000). Its barbering behavior may be counterproductive
for an undisturbed wound healing process, as these animals
might nibble on wound dressings. Most importantly, these
animals are unusually sensitive to pain and cold, and
analgesic medications are less effective (Mogil et al., 1999).
Thus, the selection of C57BL/6 mice for wound healing
experiments needs to be carefully evaluated.
Another commonly used mouse type was the albino Balb/c
strain with its different inbreeds (Balb/c ICR, Balb/c (SCID), and
Balb/c nude). BALB/c mice are more docile than C57BL/6 mice
and are particularly well known for the production of monoclonal
antibodies. BALB/c mice are used in many research fields
(cardiovascular research, cancer, infectious diseases,
neurobiology immunology, inflammation, autoimmunity). As
most substrains display high levels of anxiety, (Griebel et al.,
1993; Belzung and Berton, 1997) a familiar, calm environment is
recommended.
The ICR inbred strain serves as a general-purpose strain and
does not develop insulitis or diabetes. These mice were
recommended amongst others for drug testing and as a
control for non-obese diabetic mice3.
FIGURE 5 | (A)Mouse strains and (B) rat strains used for wound healing experiments with PnD treatment in scientific papers published between 2004 and 2020.
3https://www.jax.org/strain/009122
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CD1 are albino mice and are suggested as a general
multipurpose model, for safety and efficacy testing, as an
aging, pseudopregnancy, and surgical model4.
SCID Mice are homozygous for the severe combined immune
deficiency spontaneous mutation (Prkdcscid). They are
characterized by an absence of functional T cells and B cells,
and a normal hematopoietic microenvironment. As SCID mice
accept allogeneic and xenogeneic grafts, they are an ideal model
for cell transfer experiments. Immunodeficient mice should be
housed in a specific-pathogen-free environment to avoid
infections5.
Nude mice such as the Balb/c nude or the NMRI-Foxn1nu/
Foxn1nu inbred are characterized by thymic aplasia, which
results in immunodeficiency due to the lack of T cells. They
have no rejection responses. The mutation leads to a keratinization
defect of the hair follicles and the epidermis6. The mostly hairless
phenotype helps to avoid a shaving procedure before the wound
healing experiments. They are sensitive to cold and need to be kept
at warm temperature conditions.
TIE-2 GFP (B6.Cg-Tg287Sato/1) strain expresses Green
Fluorescent Protein under the direction of the endothelial-
specific receptor tyrosine kinase (Tek, formerly, Tie2)
promoter. This mouse type is especially appropriate to study
neovascularisation during the wound healing process as GFP-
expressing endothelial cells can be visualized via fluorescent
microscopy (Wang et al., 2018).
Rat Strains Used in Wound Healing Studies
Compared to mouse strains, fewer rat strains were used in the
investigated wound healing experiments (Figure 5B). Sprague
Dawley (SD) and Wistar rats are the most popular albino rats
used for laboratory research. SD rats are calm and less active than
Wistar rats and are therefore easy to handle. Lewis rats are highly
sensitive to the induction of autoimmune diseases as well as to
diet-induced obesity and diabetes and streptozotocin-induced
diabetes7. The Goto-Kakizaki inbred line was used as a non-
obese model of type 2 diabetes.
Wound Healing in Rodents
In general, larger wounds were created on rats than on mice (one
to two full-thickness wounds/animal with an average size of 1.52
vs. 2.11 cm2 and one to two burn wounds/animal with an average
size of 1.37 vs. 3.8 cm2 in mice and rats, respectively. Larger
wounds were radiation wounds created on rats (8 cm2) and skin
flaps (18 cm2 on mice, 30 cm2 on rats). Several approaches were
developed to get similar conditions to human wound healing
through the generation of granulation tissue and re-
epithelialization rather than contraction of the musculus
panniculus carnosus. One possibility is to investigate early
stages of wound healing in short-term studies lasting up to
8 days post wounding, where no apparent wound contraction
occurs (as performed by Tuca et al. (2016), Ertl et al. (2018)).
For longer-term experiments on full-thickness wounds,
anti-contractive tools should be chosen: Splinting wound
models use silicone or rigid plastic rings strapped around
the wound area to the underlying muscles to prevent wound
contraction. In the reviewed papers, the silicone rings were
mostly sutured or fixed with glue (Kim et al., 2012; Shohara
et al., 2012; Aguilera et al., 2014; Jin et al., 2016; Wang et al.,
2016; Peña-Villalobos et al., 2018; Wang et al., 2018; Kaushik
and Das, 2019; Arasteh et al., 2020; Nasiry et al., 2020; Sabzevari
et al., 2020). Others directly sutured scaffolds loaded with PnD
to the wound site (Yang et al., 2013; Edwards et al., 2014; Milan
et al., 2016; Montanucci et al., 2017). Edwards et al. (2014)
additionally placed a titanized mesh between the wound bed
and a collagen-based scaffold (loaded with hUC-MSC) to avoid
tissue contraction. However, these methods carry risks of
inflammation and surgical site infection (Mulholland, 2020).
Some studies did not use suturing of the scaffolds (or at least
did not mention suturing) (Nan et al., 2015; Du et al., 2016; Han
et al., 2019; Raj et al., 2019).
Beiki et al. (2017) observed that scaffolds produced from liquid
WJ-ECM accelerated wound closing and counteract wound
contracture during the observation period of 18 days. Also, a
hyaluronic acid hydrogel with or without solubilized hAM
counteracted wound contracture (Murphy et al., 2017). We
could see from Vonbrunn et al. (2020) that the application of
stiff carrier materials for PnD such as electrospun Poly(ε-
caprolactone)/poly(l-lactide) (PCL/PLA) could enable
uncomplicated experiments on rodents without suturing and
could open new therapeutic approaches due to the anti-
contractive properties of the material. Still, numerous long
term-studies were performed on rodents, where no anti-
contractive strategies were applied. This hinders the
reproducibility of data, and the studies’ outcomes seem
questionable. Anti-contractive properties are strongly needed,
especially if PnD were just subcutaneously injected around the
wound area or are topically applied in fluid or gel-like solutions or
as soft membranes.
Another problem for the reproducibility of data is that there is
significant variability in the application of wound dressings. Wound
dressings are used to keep the wound area free of contamination. In
the majority of the analyzed studies on rodents, it is not described
whether a wound dressing was applied or not (Figure 6). Thus, it is
difficult to evaluate the wound healing progress under unspecified
experimental settings. In two studies, wounds were left open (Liu
et al., 2014; Liu et al., 2016).
A popular wound dressing material for rodents is a dressing
with Tegaderm™ plaster. It was applied without suturing
(Zebardast et al., 2010; Tuca et al., 2016; Ertl et al., 2018; Bian
et al., 2020; Vonbrunn et al., 2020), sutured onto the skin (Eylert
et al., 2021), or was combined with a cohesive bandage (Arasteh
et al., 2020). Other possibilities for wound dressings are fat gauze
or oil gauze – with and without suturing to the skin (Montanucci
et al., 2017; Motamed et al., 2017; Song et al., 2017; Gao et al.,
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As unsutured plasters were partly detached from the wounds
after a few days, we recommend removing the plasters 3 days post
wounding, and thereafter leaving the wounds open to get
standardized conditions for the wound healing process.
An accurate description of the advantages or disadvantages of
used wound dressings in future publications would be helpful to
standardize experiments and to enable comparability of the
experiments concerning the healing outcome.
Wound Healing in Large Animals
On large animals, experiments were mainly performed on pigs.
Pigs have the advantage that the porcine skin more closely
correlates to human skin in thickness and structure than rodent
skin. Wound closure in pigs is similar to wound healing in humans
because the musculus panniculus carnosus is vestigial or absent in
most body regions. Therefore, wounds heal by re-epithelialization
rather than by contraction, and no anti-contractive strategies or
devices are needed. However, experiments on pigs are cost-
intensive and far more complex with respect to medication,
anesthesia, and wound dressing, making them mainly useful for
preclinical trials of therapies (Boyko et al., 2017).
As the number of animals in experiments is limited due to costs
and husbandry, multiple wounds were performed on each subject.
Three studies included in the review utilized pigs as experimental
animals (Han et al., 2014; Murphy et al., 2020; Eylert et al., 2021).
Multiple wounds were created on the back of the animals (minimum
4, maximum not specified) and topically treated with PnD for
3–4 weeks. (Eylert et al., 2021) performed multiple full-thickness
burn wounds with a size of 5 × 5 cm in diameter. It was shown that
wounds treated with Integra® seeded with hUC-MSC at a low dose
(40,000 cells/cm2) regenerated wounds most efficaciously. Wounds
were dressed with a layer of topical antibiotics, fat gauze, multiple
layers of gauze, Tegaderm®, and a compression jacket. The initial
wound margins were marked by a skin stapler. Wound dressing
changes were performed two to three times per week.
Murphy et al. (2020) created eight 4 × 4 cm square-shaped full-
thickness wounds on the central back and marked initial wound
margins by tattooing before excision. Amnion-hydrogel and amnion
powder treatments achieved themost rapid wound healing compared
to commercially available Amniograft®, followed by hydrogel only,
untreated wounds, or graft jacket, respectively. The treatment with
the graft jacket alone led to the worst healing outcome (largest wound
area, most contraction, least epithelialization). The wound dressing
consisted of a topical antibiotic cream, Tegaderm® and a cast
padding, cohesive bandaging, a protective saddle, and a jacket.
Han et al., 2014 (Han et al., 2014) created circular full-thickness
wounds (diameter 3 cm). Collagen-chitosan-based scaffolds loaded with
microencapsulated VEGF gene-modified hUC-MSC improved the
vascularization of the tissue-engineered dermis and induced a better
wound healing than controls (microencapsulated hUC-MSC, empty
capsule, andPBS-treated group). Thewounddressingwasnot described.
One case report described the wound treatment on dogs
(Ribeiro et al., 2014). Two dogs suffering from non-healing
skin lesions were treated with poly(vinyl alcohol) hydrogel
(PVA) membrane supplied with low-dose UC-MSC 0.1 ×
10^6 cells/cm2. hUC-MSC induced significant progress in skin
regeneration with the decreased extent of ulcerated areas.
Two studies were performed on rabbits, where full-thickness
wounds were treated with rabbit BM-MSC either in combination
with hAM (Kim et al., 2009) or with human placenta extract
(Akela et al., 2013).
SUMMARY AND CONCLUSION
The pre-clinical evidence of our review indicates that PnD-based
therapy is in general effective to promote cutaneous wound
healing. The significant amount of variability between types,
dosage, and application mode of PnD, as well as between the
animal models, hinders the comparability of data. Perinatal cells
FIGURE 6 | Types of wound dressing applied to animal cutaneous wounds.
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were the most commonly used PnD type, but only a tiny minority
of studies compared the effect of applying different cell
concentrations or modes of administration. Perinatal cell
treatment worked at both low and high dosing, and further
studies are required to evaluate the most optimal cell therapy.
Treatment with perinatal cell-derived CM achieved similar
beneficial effects as with cells, and frequent multiple
applications of CM showed better outcomes than single- or
two-fold treatments. Perinatal cell-derived sEV showed similar
or even better beneficial effects on wound healing than perinatal
cells. No studies compared different dosages of perinatal cell-sEV.
The combination of cells and perinatal tissue membranes
achieved better results on wound healing than either cells or
tissue alone, and the combination of perinatal tissue extracts with
cells achieved better results than tissue extracts without cells.
As an inadequate characterization of PnD may lead to a false
identification of the PnD that hinders reproducibility and
comparability of various studies, we propose the following
guidelines for the PnD characterization before their
application in pre-clinical studies:
1) A detailed and traceable cell/tissue isolation procedure – if
PnD are commercially available, the company should be
indicated (catalog and lot numbers, etc.).
2) Each PnD should be characterized by at least two in vitro
methods: For cells, this should include the phenotype
(morphology, immunolabeling for mesenchymal/epithelial
markers, stem cell markers) and the ability to differentiate
into all three germ layers (if stem cells are used). For the
tissues, histology and immunolabeling to prove the identity/
characteristics of the PnD, should be provided. In the case of
purchased cells/tissues, the authors should indicate the main
characteristics of PnD, as provided by the company.
3) Functional tests on cytotoxicity, promotion of proliferation,
migration, and differentiation should be performed to ensure
the quality of the PnD.
4) Dosage of PnD, characteristics of the wound, and the entire
operating procedure, with mode and timing of application,
should be described in detail so that the methodology is fully
reproducible.
In addition, well-defined and standardized animal models are
required for a comparison of outcome measures between studies.
They may help to minimize redundancy in animal
experimentation in line with the Replacement, Reduction, and
Refinement (3R) principles for more ethical use of animals in
research (Russell and Burch, 1960). The needs for standardization
range from the choice of animal species and strains (with a
preference for docile strains without barbering behavior and low
anxiety levels) to precise experimental settings with regard to the
extent and deepness of wounding and the adequate wound
dressing. On rodents, anti-contractive strategies, ideally
without suturing of devices, should be considered for long-
term experiments (longer than 1 week) on full-thickness wounds.
An accurate description of the advantages or disadvantages of
methods used in future publications would be helpful to
standardize experiments and to enable comparability of the
experiments concerning the healing outcome.
In conclusion, PnDhave a promising potential to be widely used
as a source of biological material to assist wound healing, now and
in the future. Further concerted actions will be needed to bridge the
gap between PnD basic research, pre-clinical studies, and their
translation into the clinic. The COST SPRINT Action (CA17116)
aims to provide comprehensive and evidence-based guidelines on
all levels (Silini et al., 2020) to promote the safety and efficacy of the
therapeutic use of PnD. The present review will contribute to the
establishment of standards of care in wound healing.
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